The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia
Launched by UNIVERSITY OF TARTU · May 31, 2024
Trial Information
Current as of February 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a special scoring system based on CT scan signs can help doctors identify which parts of the bowel are still healthy and can be saved in patients with acute mesenteric ischemia (AMI). AMI is a serious condition where blood flow to the intestines is blocked, and quickly determining whether the affected bowel can be treated with therapy is crucial. The goal is to improve the accuracy of CT scans by combining various symptoms to create a reliable score that indicates whether the bowel can be saved, potentially avoiding surgery to remove damaged sections.
To participate in this trial, individuals need to be part of the larger AMESI study and must have suspected or confirmed cases of AMI. They should also have had a full CT scan of the abdomen using a special dye called contrast media. Unfortunately, scans that didn’t use this dye or only covered part of the abdomen won’t qualify. Participants can expect to undergo the standard CT imaging, and their results will help develop better tools for diagnosing and treating this serious condition in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant in AMESI study
- • confirmed or suspected acute mesenteric ischaemia
- • CT scan of the entire abdominal cavity / full body using intravenous contrast media is available
- Exclusion Criteria:
- • Scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.
Trial Officials
Joel Starkopf
Study Chair
University of Tartu, Department of Anaesthesiology and Intensive Care
About University Of Tartu
The University of Tartu, located in Estonia, is a prestigious research institution recognized for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the broader medical community. With a focus on ethical practices, collaboration, and scientific excellence, the University of Tartu is dedicated to fostering groundbreaking studies that address critical health challenges and enhance the understanding of complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tartu, , Estonia
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0